Answers are grounded in this paper and cite their sources.
This descriptive retrospective study looked through the very considerable number of 41,775 cases of hyaluronic acid filler injections.1 Several inbuilt safety parameters were set up by the group's administration to limit complications, including injection to the glabella and the tip of the nose. These regions have been demonstrated to be among the most problematic not only for intravascular injections but also for serious ramifications (eg, blindness and neurological deficit) related to intravascular filler injections; exclusion of these sites, albeit laudable, might therefore distort the acute complication rate found in this series.2,3 However, the use of nasal cannulation in the authors’ clinic has been responsible for multiple causes of blindness and would seem to be a flawed technique or at least one that requires greater scrutiny.4 I did find some difficulties understanding a few aspects of this paper. The single case of conjunctivitis from upper eyelid injection (I am assuming this is A-frame injection) explored here was very interesting but is distinctly unusual and not something with which I am familiar. I thus found it unclear how this was diagnosed as due to the filler, and could not understand the authors’ concept that it is possible to extrapolate from a single case the risk of this injection in this region in more general terms. Surely a single case may occur at any stage by chance alone and should not be taken as a risk predictor or used in comparison against other areas as is done here. Nonetheless this is a curious case that I think needs further elaboration. Other concepts I could not quite understand were peripheral puffiness, or what periorbital puffiness meant as an injection site. I was disconcerted that apart from intravascular injection I had to wait for the Results section to find what other acute reactions were being sought by the group in addition to the intravascular issues. It is no surprise that when the tip of the nose and the glabella are removed, the next most common region for intravascular accidents is the nasolabial fold, although I was surprised that the nose did not feature more highly. The nasolabial fold is a common site for injection and its proximity to the facial artery means that standard injection techniques for correction involve risks due to variability in the horizontal and vertical positioning of the artery. Experience is an interesting issue in injecting. Certainly experience has been found not to ensure lack of intravascular injection with filler,5 but it is interesting that the Abstract of this study alluded to experience, as well as anatomic knowledge, being important. Yet in this paper, the group with less than 1 year of experience fared better than those with 1 to 5 years (close to but without quite making statistical significance), but both groups fared worse than those with over 5 years of experience. It is interesting to postulate that those with limited experience accept their lack of knowledge and inject carefully and according to protocol, whereas those with 1 to 5 years’ experience may become a little too confident but still lack the in-depth anatomic knowledge of those with many more years’ experience. The forehead issues with nerve damage may well be a result of trying to be too kind. Anesthetizing the area with nerve blocks before forehead treatment may allow passage of the cannula across nerve plexuses to be more damaging but not immediately painful. If the patient had no nerve blocking, they are very likely to stop the practitioner before actual damage would be seen because of the pain experienced. Although the body of the article seems to suggest a No. 18 cannula is mandatory, it seems from the table that a sharp needle was allowed and the direction of cannula use was not discussed, at least I could not find this information. To be safest, cannulas should be directed across axial vessels rather than in line with them. This is true for all areas of the face. It is often the central features of the face that are at particular issue with intravascular injection and vascular compromise and prone to other issues discussed here, for example, allergy. The Asian face is particularly vulnerable to safety issues because many features that patients wish to have enhanced or corrected (forehead, midcheek, nose, chin, and glabella) are innately associated closely with branches of the facial, maxillary, or ophthalmic arteries. To keep as safe as possible requires a thorough knowledge of facial vascular anatomy, use of appropriate continual movement of needle or syringe, slow careful treatment, and injection of small aliquots rather than large static boluses. Articles such as this reporting a low complication rate and good retrospective data are important to analyze as they give insights into clinic practice and safety measures to be adopted and examined. Dr Goodman is a researcher, author, consultant, and speaker for AbbVie/Allergan (Irvine, CA); a researcher, author, consultant, and speaker for Galderma (Lausanne, Switzerland); and a researcher, consultant, and speaker for Caliway (Taipei, Taiwan). The author received no financial support for the research, authorship, and publication of this article.
No takes yet. Share an insight, caveat, or question.
Greg Goodman (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: